CDR2L

Protein identityUniProt · HPA

UniProt accession

Q86X02

Gene

CDR2L

Ensembl

ENSG00000109089

Chromosome

17

Canonical length

465 aa

Protein class

Predicted intracellular proteins

Subcellular location

Cytosol

OverviewNCBI Gene

Enables identical protein binding activity. Predicted to be involved in Golgi to secretory granule transport and vesicle transport along microtubule. Predicted to be located in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

465 residues, UniProt reviewed canonical sequence.

>Q86X02|CDR2L
     1  MRRAAGMEDF SAEEEESWYD QQDLEQDLHL AAELGKTLLE RNKELEGSLQ QMYSTNEEQV
    61  QEIEYLTKQL DTLRHVNEQH AKVYEQLDLT ARDLELTNHR LVLESKAAQQ KIHGLTETIE
   121  RLQAQVEELQ AQVEQLRGLE QLRVLREKRE RRRTIHTFPC LKELCTSPRC KDAFRLHSSS
   181  LELGPRPLEQ ENERLQTLVG ALRSQVSQER QRKERAEREY TAVLQEYSEL ERQLCEMEAC
   241  RLRVQELEAE LLELQQMKQA KTYLLGPDDH LAEALLAPLT QAPEADDPQP GRGDDLGAQD
   301  GVSSPAASPG HVVRKSCSDT ALNAIVAKDP ASRHAGNLTL HANSVRKRGM SILREVDEQY
   361  HALLEKYEEL LSKCRQHGAG VRHAGVQTSR PISRDSSWRD LRGGEEGQGE VKAGEKSLSQ
   421  HVEAVDKRLE QSQPEYKALF KEIFSRIQKT KADINATKVK THSSK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CDR2L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability

Unknown

Secreted

No

Transmembrane segments

0

Mean surface accessibility (rSASA)

0.56

Highest tissue expression

59 nTPM

Expression across tissuesHPA

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CDR2L.

Disease | AutoantibodyPubMed

Conditions in which antibodies against CDR2L are reported. Each links to that disease's full target list.

Showing 0 of 1 — disease pages carrying at least 10 antigens.

ReferencesPubMed · IEDB

Publications for CDR2L from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)

0.83

gnomAD pLI

0

gnomAD missense Z

1.73

DepMap mean gene effect

-0.05

DepMap dependency class

none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

• Golgi to secretory granule transport
• vesicle transport along microtubule

Molecular functions

• identical protein binding

Protein domainsUniProt · Pfam · InterPro

• Cerebellar degeneration-related protein 2

KeywordsUniProt

• Coiled coil
• Phosphoprotein

InteractionsUniProt · HPA

Protein binding partners of CDR2L in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

• BFSP2
• C4orf46
• CDR2
• PSME3
• YWHAE
• YWHAG
• YWHAH
• YWHAQ
• YWHAZ